| Literature DB >> 35402305 |
Ewerton Cristhian Lima de Oliveira1, Kauê Santana da Costa2, Paulo Sérgio Taube2, Anderson H Lima3, Claudomiro de Souza de Sales Junior1.
Abstract
Peptides comprise a versatile class of biomolecules that present a unique chemical space with diverse physicochemical and structural properties. Some classes of peptides are able to naturally cross the biological membranes, such as cell membrane and blood-brain barrier (BBB). Cell-penetrating peptides (CPPs) and blood-brain barrier-penetrating peptides (B3PPs) have been explored by the biotechnological and pharmaceutical industries to develop new therapeutic molecules and carrier systems. The computational prediction of peptides' penetration into biological membranes has been emerged as an interesting strategy due to their high throughput and low-cost screening of large chemical libraries. Structure- and sequence-based information of peptides, as well as atomistic biophysical models, have been explored in computer-assisted discovery strategies to classify and identify new structures with pharmacokinetic properties related to the translocation through biomembranes. Computational strategies to predict the permeability into biomembranes include cheminformatic filters, molecular dynamics simulations, artificial intelligence algorithms, and statistical models, and the choice of the most adequate method depends on the purposes of the computational investigation. Here, we exhibit and discuss some principles and applications of these computational methods widely used to predict the permeability of peptides into biomembranes, exhibiting some of their pharmaceutical and biotechnological applications.Entities:
Keywords: blood-brain barrier; cell membrane; cell-penetrating peptides; drug system carriers; machine learning; peptides; pharmacokinetics; structure activity
Mesh:
Substances:
Year: 2022 PMID: 35402305 PMCID: PMC8992797 DOI: 10.3389/fcimb.2022.838259
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 5.293
Figure 1Schematic representation of cell membrane showing its main chemical lipidic and protein components.
Figure 2Schematic representation of the blood-brain barrier, showing its main cell components (pericytes, astrocytes, and endothelial cells) and localization in the brain capillary wall.
Figure 3Acceptable tPSA values for the cell membrane permeability. Chameleonic molecules are able to change their conformation to expose polar groups in an aqueous phase, however hide them when translocating through the cell membranes.
Comparison between the chemical spaces and cheminformatic filters of peptides and commercial drugs with bioavailability.
| Molecular properties | Oral drugs | Peptides | ||||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
|
| ≤ 500 | – | ≤ 1,000 | ≤ 700 | 27.03 ≤MW ≤5,036.65 | 331.48 ≤ MW≤ 3,750.51 |
|
| ≤ 5 | – | -2 ≤ cLogP ≤ 10 | ≤ 7.5 | -17.87 ≤ cLogP ≤ 39.89 | -42.12 ≤ cLogP ≤ 2.97 |
|
| – | ≤ 14 | ≤ 250 | ≤ 200 | ≤ 2,064.83 | 101.29 ≤ tPSA ≤ 1,782.83 |
|
| – | – | – | ≤ 0.55 | – | 0.37 ≤ Fsp3 ≤ 0.84 |
|
| – | ≤ 10 | ≤ 20 | ≤ 20 | ≤ 209 | 9 ≤ NRB ≤ 137 |
|
| ≤ 5 |
| ≤ 6 | ≤ 5 | ≤ 76 | 4 ≤ HBD ≤ 69 |
|
| ≤10 |
| ≤ 15 | ≤ 10 | ≤ 71 | 5 ≤ HBA ≤ 55 |
|
| – | – | – | – | – | ≤ 10 |
*Investigated oral available peptides; **Investigated the linear and cyclic pentapeptides; ***Investigated CPP structures and described their chemical space.
Table edited from de Oliveira et al. (2021).
Figure 4Representation of main categories on machine learning state-of-art, divided between supervised learning, such as classification and regression problems; and unsupervised learning that includes clustering and dimensionality reduction problems.
Figure 5Structure- and sequence-based molecular descriptors that are applied in the prediction of biomembrane penetrating peptides.
Figure 6Mechanisms of passive penetration of CPPs into the cell membrane (energy-independent mechanisms). (A) Passive diffusion (spontaneous translocation), (B) Peptide aggregation with pore formation, (C) endocytosis. The panels (D) and (E) represent some subsequent molecular events in the cell: (D) endosomal membrane lysis and (E) translocation through the cell membrane.
List of names, primary structure, biological activities, and references for the cited peptides with therapeutic effect against neurodegenerative diseases, as well as BBB shuttle property.
| Peptide names | Amino acid sequences | Biological activities | References |
|---|---|---|---|
| Ziconotide | CKGKGAKCSRLMYDCCTGSCRSGKC | Blocker of Ca2+ channel, preventing neuronal damage | ( |
| Exenatide | HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS | Inhibitor of GLP-1R | ( |
| PhTx3-3 | GKCADAWESCDNYPCCVVNGYSRTCMCSANRCNCDDTKTLREHFG | Blocker of Ca2+ channel, exocytosis, and glutamate release | ( |
| PhTx3-4 | SCINVGDFCDGKKDCCQCDRDNAFCSCSVIFGYKTNCRCE | Blocker of Ca2+ channel, exocytosis, and glutamate release | ( |
| P110 | YGRKKRRQRRRGGDLLPRGS | Inhibitor of DRP1 | ( |
| Ba-V* |
| Inhibitor of mitochondrial permeability transition, preventing PD and AD | ( |
| Transportan 10 | AGYLLGKINLKALAALAKKIL | BBB shuttle of small molecules (e.g. dopamine and vancomycin) | ( |
| Angiopep-2 | TFFYGGSRGKRNNFKTEEY | BBB shuttle of small molecules (e.g. neurotensin and coumaric acid) | ( |
| SynB1 | RGGRLSYSRRRFSTSTGR | BBB shuttle of small molecules (e.g. doxorubicin, Benzylpenicillin, and M6G) | ( |
| SynB3 | RRLSYSRRRF | BBB shuttle of small molecules (e.g. doxorubicin, | ( |
*Ba-V is not only one peptide, but a family of peptides.
List of names, primary structure, biological activities, and references for the cited peptides with antimicrobial activity.
| Peptide names | Amino acid sequences | Biological activities | References |
|---|---|---|---|
| GNLY | GRDYRTCLTIVQKLKKMVDKPTQRSVSNAATRVCRTGRSRWRDVCRNFMRRYQSRVIQG … LVAGETAQQICEDLR | Antibacterial | ( |
| Mersacidin | MSQEAIIRSWKDPFSRENSTQNPAGNPFSELKEAQMDKLVGAGDMEAACTFTLPGGGGVCTLTSECIC | Antibacterial activity | ( |
| OH-CATH | MEGFFWKTLLVVGALAIGGTSSLPHKPLTYEEAVDLAVSIYNSKSGEDSLYRLLEAVPPPE … WDPLSESNQELNFTIKETVCLVAEERSLEECDFQEDGAIMGCTGYYFFGESPPVLVLTCK … PVGEEEEQKQEEGNEEEKEVEKEEKEEDEKDQPRRVKRFKKFFKKLKNSVKKRAKKFFK…KPRVIGVSIPF | Antibacterial activity | ( |
| DEFB114 | MRIFYYLHFLCYVTFILPATCTLVNADRCTKRYGRCKRDCLESEKQIDICSLPRKICCTEKLY…EEDDMF | Broad-spectrum antibacterial, antifungal activities | ( |
| Buforin II | TRSSRAGLQWPVGRVHRLLRK | Broad spectrum antibacterial and antifungal activities | ( |
| Omiganan | H- | Broad-spectrum antifungal, antibacterial | NCT02576847** |
| Novexatin | cyclo[RRRRRRR] | Antifungal activity | NCT02933879** |
| hLFroad-spectrum(1-11) | GRRRRSVQWCA | Broad-spectrum antibacterial and antifungal activities | NCT00509847** |
| Demegel | FAKKFAKKFKKFAKKFAKFAFAF | Antibacterial, antifungal | ( |
| ETD151 | DKLIGSCVWGAVNYTSNCRAECKRRGYKGGHCGSFANVNCWCET | Antifungal activity | ( |
| Bacitracin* | Unk-L-dEIK(1)-dOrn-I-dFH-dDN-(1) | Antibacterial activity | ( |
| Colistin* | Unk-Dab-T-Dab-Dab(1)-Dab-dLL-Dab-Dab-T(1) | Antibacterial activity | ( |
| Polymyxin B* | Unk-Dab-T-Dab-Dab(1)-dDab-dFL-Dab-Dab-T(1) | Antibacterial activity | ( |
*Bacitrin, Colistin, and Polymyxin B are commercially available peptide-based antibiotics.
**The alphanumeric codes correspond to identifiers of the ClinicalTrials.gov of the US National Library of Medicine.